This Phase 3 clinical trial is open to both participants who have previously been participating in the Dimension or Surveyor studies, as well as those who have not. The study is currently enrolling patients for its open label phase to receive the investigational drug, SAGE-718

A Phase II, Multicentre, Randomised, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of IPN10200 for the Treatment of Blepharospasm in Adults

This research study will gather clinical information about you and your health and collect biological samples. Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. Study participants will be individuals affected by HD or who come from an HD family who are eligible and willing to participate in Enroll-HD. The study is available for English and Spanish-speaking participants

This study aims to explore how well people with MSA tolerate the drug ONO-2808, its effectiveness, the appropriate doses that are safe, and how the drug functions in the body. If you are 30-80 years old, diagnosed with MSA-C or MSA-P, experiencing motor symptoms for less than 5 years, and can walk 10 steps back and forth, you might be eligible to join. The study lasts for 34 weeks, with some visits conducted at your home by a study nurse

Observational study of Deep Brain Stimulation patients with Abbott DBS system conducted to gather clinical data on how Abbott DBS systems are being used in routine clinical practice

Mapping the Future of Parkinson's Disease is a national initiative that offers genetic testing for clinically relevant Parkinson's-related genes and genetic counseling at no cost for people with Parkinson's disease, in English or Spanish. You can participate from home.